[PERSONALIZED EMAIL TOPPER FROM BENEFIT STAFF]

***MISSED THE CONFERENCE? GET CAUGHT UP AND HELP SPREAD THE WORD***

Recently, BENEFIT Kids was honored to present the results of several key studies addressing multidrug-resistant tuberculosis (MDR-TB) prevention and treatment for children at the Union World Conference on Lung Health in Paris.

Treatment of MDR-TB in children still lags dramatically behind recent advances in adult MDR-TB treatment, and the studies addressed these key evidence gaps and barriers — informing efforts to produce more child-friendly, better tasting medicines and formulations, as well as to improve uptake, acceptability and outcomes among children.

**Learn more about BENEFIT Kids and the information we presented at the Union Conference at** [**our refreshed website**](https://blogs.sun.ac.za/dttc/benefit-kids/) **and please consider sharing the news articles and graphics with your networks and on your social channels to help us spread the word about these critical findings and their impact.**

***HELP SPREAD THE WORD***

*Media coverage from the Union Conference to share:*

* **NPR:** ["WHO says we can ‘write the final chapter in the story of TB.’"](https://www.npr.org/sections/goatsandsoda/2023/11/16/1211062206/who-says-we-can-write-the-final-chapter-in-the-story-of-tb-how-close-are-we)
* **BBC Africa:** ["Drug trial offers hope for TB prevention"](https://www.bbc.com/news/live/world-africa-67176390?ns_mchannel=social&ns_source=twitter&ns_campaign=bbc_live&ns_linkname=65560f762ea49e2bc009b346%26Drug%20trial%20offers%20hope%20for%20TB%20prevention%262023-11-16T13%3A24%3A19.900Z&ns_fee=0&pinned_post_locator=urn:asset:1371439b-9871-47a5-abdd-805adae6258f&pinned_post_asset_id=65560f762ea49e2bc009b346&pinned_post_type=share)
* **Devex (US):** ["Study: Common antibiotic reduces risk of drug-resistant TB"](https://www.devex.com/news/study-common-antibiotic-reduces-risk-of-drug-resistant-tuberculosis-106583)
* **Agence France-Presse:** ["Common drug halves risk of drug-resistant tuberculosis"](https://www.barrons.com/news/common-drug-halves-risk-of-drug-resistant-tuberculosis-researchers-8c12a081)

*Talking points to use in social media posts:*

* Children with multidrug-resistant tuberculosis (MDR-TB) are a neglected population suffering from a largely neglected disease.
* Right now, the treatment journey for children with MDR-TB and their caregivers can be unnecessarily long and harrowing.
* Most of the drugs currently given to children with MDR-TB were developed 50 to 60 years ago, are more painful and less effective, and have unpleasant side effects.
* There has been progress made on adult treatment, but children aren’t just “little adults” — and developing drug formulations for children poses unique challenges.
* BENEFIT Kids is dedicated to researching and accelerating the adoption of innovative MDR-TB treatment regimens and prevention methods for children of all ages, in order to reduce illness and death among this vulnerable population.
* Supported by funding from Unitaid, BENEFIT Kids is bridging knowledge gaps and producing critical evidence on dosing, safety, and efficacy.

*Infographics and factsheets to use:*



[**Download this graphic (and the full factsheet) here**](https://drive.google.com/drive/folders/1hs04EtSnrbBFWR0qehZpwpHIspM3G6QK?usp=sharing)



[**Download this graphic here**](https://drive.google.com/drive/folders/1hs04EtSnrbBFWR0qehZpwpHIspM3G6QK?usp=sharing)



[**Download this graphic here**](https://drive.google.com/drive/folders/1hs04EtSnrbBFWR0qehZpwpHIspM3G6QK?usp=sharing)



[**Download this infographic here**](https://drive.google.com/drive/folders/1hs04EtSnrbBFWR0qehZpwpHIspM3G6QK?usp=sharing)